The first two editions of this Blog have dealt with the immense scope of M-Abs as a 
Novel Therapeutic Modality and HOW they are actually manufactured in Bio-Labs . We will herewith enlist the specific M-Abs and their designated role in specific disorders.
The first Monoclonal Antibody was approved by FDA ( Muromonab CD3 ) in 1986 – for the Treatment of Renal Transplant Rejections. Therefore, the exciting Modern Era of MONOCLONAL ANTIBODIES is already three decades old.
Mechanisms of Action of M-Abs are many, as described below, and most of them are very similar to our Human IgG Antibodies. 
Agglutination = clumping of pathogens, followed by Phagocytosis. Opsonin action, meaning BINDING to pathogens to make them vulnerable to phagocytosis by immune cells of our Innate Immunity. Neutralization of Toxins. Destruction by Killer T-cells after M-Abs binding to targeted cells. Blocking of Receptor Sites for the Spike Proteins of COVID 19 virus, by the ANTIBODY COCKTAIL therapy
Examples of M-Abs
Breast Cancer ( HER2 receptor protein ) is treated with TRANSTUZUMAB
Rheumatoid arthritis ( CD20 protein ) is treated with
RITUXIMAB
EARLY COVID-19 ( Spike Protein ) is treated with a COCKTAIL of CASIRIVIMAB and IMDEVIMAB
RABISHIELD is a M-Ab for immediate Post exposure Rabies Prophylaxis. ( PERP ) following Dog bites.
Multiple Sclerosis ( CD52 protein ) is treated with ALEMTUZUMAB 
The same M-Ab applies to certain Leukemias.
Inflammatory Bowel disease ( TNF – alpha ) is treated with ADALIMIMAB or INFLIXIMAB
PSORIASIS ( TNF alpha ) is treated with ADALIMIMAB or INFLIXIMAB
Rheumatoid Arthritis ( CD20 protein ) along with Autoimmune Hemolytic Anemias and Non-Hodgkin Lymphomas, are treated with RITUXIMAB
Macular Degeneration in eyes – age related ( VEGF- A protein ) is contained by direct injections in the eye – using RANIBIZUMAB
Monoclonal Antibodies are undergoing extensive Research for the cure of many die-hard Disorders, and are the HOTCAKES for the future of Therapeutics.
9898003607